<DOC>
	<DOC>NCT01081782</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Adult male or female aged 1855 years inclusive at screening Patients who have a definite diagnosis of relapsingremitting Multiple Sclerosis Multiple Sclerosis course other than relapsingremitting multiple sclerosis History of malignancy History of clinically significant chronic disease of the immune system (other than Multiple Sclerosis) Inability to undergo Gdenhanced MRI scans Diagnosis of diabetes mellitus (type I or type II)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>ONO-4641</keyword>
</DOC>